Teva Pharmaceutical Industries Limited reported $14.1B of revenue over the trailing twelve months, −15% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $14.1B (to Q1 2026). Net Income: $1.56B, trailing twelve months to Q1 2026. Free Cash Flow: $1.17B, trailing twelve months to Q1 2026. Op Margin: 17%, trailing twelve months to Q1 2026.

TEVATeva Pharmaceutical Industries Limited

HealthcareUSD

$37.96

$16.3752 weeks$38.10

TEVA as reported

Teva Pharmaceutical Industries Limited reported $14.1B of revenue over the trailing twelve months, −15% on the year before. 10 reported series are charted on this page, each one as filed.

$14.1B

Revenue, trailing twelve months · to Q1 2026 · −15% against the twelve months before

Net Income: $1.56B
Net Income · −222% year on year · trailing twelve months to Q1 2026
Free Cash Flow: $1.17B
Free Cash Flow · +53% year on year · trailing twelve months to Q1 2026
Op Margin: 17%
Op Margin · trailing twelve months to Q1 2026

Every series Ryufin has for TEVA, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$14.1B	−15%	Q1 2026
Net Income	$1.56B	−222%	Q1 2026
EPS	$1.33	−216%	Q1 2026
Gross Margin	82%	n/a	Q1 2026
Op Margin	17%	n/a	Q1 2026
Net Margin	14%	n/a	Q1 2026
ROE	11%	n/a	Q1 2026
ROA	2.2%	n/a	Q1 2026
ROIC	24%	n/a	Q1 2026
Free Cash Flow	$1.17B	+53%	Q1 2026